Press Release

 

SkylineDx signs 10th collaboration agreement under Falcon Melanoma R&D Program

 

ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 23, 2020: last week, SkylineDx signed the 10th collaboration agreement with an academic partner for research under the extensive Falcon R&D Program to further validate both melanoma (skin cancer) tests. The 10 clinical centers represent 6 countries on 3 continents with data on over 3,500 cutaneous melanoma patients. The data generated will be used in the validation of the Merlin and Peregrine assay. The Merlin assay has been developed to predict a patient’s risk of having metastasis in the sentinel lymph node. If a patient is identified as low-risk, the surgery that removes the sentinel lymph node can be safely avoided. The Merlin assay is developed on a US patient dataset [2] and validated in a European dataset [3]. The group of patients without metastasis in their sentinel lymph nodes, are currently considered low risk, although a significant number of patients will see their melanoma returning within 5 years. The Peregrine assay has been developed to identify patients at high risk of disease recurrence within this group of patients now considered low-risk, so treatment options can be discussed [4-5].

 

 “I am very pleased that we are continuing our research with global partners for retrospective validation studies. Even more clinical groups have expressed interest to collaborate and are likely to be added in the near future to this research initiative. Processing of the biobanked samples is in full swing and we expect to have all the results for analyses by the end of 2020. The peer reviewed publication will follow shortly in 2021”, explains Dharminder Chahal, CEO SkylineDx. 

 

About Merlin & Peregrine

Both assays are using the CP-GEP model, a powerful algorithm that calculates the risk of metastasis in a patient’s sentinel lymph nodes (predictive use) and the risk of the melanoma returning (prognostic use). The model is able to calculate risk on an individual basis through a combination analysis of 8 genes from the patient’s primary tumor, the tumor thickness and the patient’s age. The model has been previously published in JCO Precision Oncology [2]. The predictive use of the CP-GEP model is the main focus of the Merlin Study Initiative. The prognostic use of the CP-GEP model is the main focus of the Peregrine Study Initiative. Both are developed under the wings of the Falcon R&D Program. More information on www.falconprogram.com.

 

About SkylineDx

SkylineDx is a biotechnology company, mainly focused on research & development of molecular diagnostics in oncology. The company is headquartered in Rotterdam (the Netherlands) and complemented with a field medical and scientific affairs team in the US and a CAP/CLIA certified laboratory in San Diego (California). SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predict a patient’s response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. To learn more, please visit www.skylinedx.com.  

 

Footnotes

  1. Link to this press release on website SkylineDx (click here)

  2. Bellomo et al., 2020. Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precis Oncol 4:319-334 (click here)

  3. Mulder & Dwarkasing et al., 2019. Validation of a clinicopathological and gene expression profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma. Annals of Oncology30:2019(issue suppl 5; mdz255.014). Click here.

  4. Eggermont et al., 2020. Using a clinicopathologic and gene expression model to identify melanoma patients at high risk for disease relapse. J Clin Oncol 38:2020(suppl; abstr 10068). Click here.

  5. Wever et al., 2020. Identification of stage IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. J Clin Oncol 38:2020(suppl; abstr e22088). Click here.

 

 

***


Our news

SkylineDx signs 10th collaboration agreement under Falcon Melanoma R&D Program

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 23, 2020: last week, SkylineDx signed the 10th collaboration agreement with an academic partner for research under the extensive Falcon R&D Program to further validate both melanoma

read more

Prognostic model reveals high-risk melanoma patients that need a clinical trial

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 14, 2020: SkylineDx announces the publication of two ASCO abstracts describing a biomarker that identifies a subgroup of skin cancer (cutaneous melanoma) patients that could benefit from

read more

Private health insurance reimburses MMprofiler with SKY92 for patients United Kingdom

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 12, 2020: Everything Genetic Ltd has partnered with a leading private health insurance company in the UK to design an access strategy for patients with multiple myeloma (blood cancer) to

read more

SkylineDx launches melanoma test in United States to support cancer care

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), April 22, 2020: SkylineDx announced today that the Merlin Assay for melanoma is officially added to their test menu and available as Laboratory Developed Test from their CAP/CLIA lab in San

read more

Skin cancer test reduces need for surgery

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), April 15, 2020: SkylineDx in collaboration with the Mayo Clinic published yesterday its first study describing a diagnostic test that could reduce up to 42% of surgical interventions used to

read more

SkylineDx and BioInvent to collaborate on patient stratification to maximize impact of treatment with BI-1206

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), March 24, 2020: SkylineDx today announces an agreement with BioInvent International AB (OMXS: BINV) to characterize the gene expression and immunological signatures in tumors of patients pre-

read more

National Research Cancer Institute UK confirms benefit molecular profiling in multiple myeloma

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), March 17, 2020: multiple myeloma (blood cancer) patients with a high risk or aggressive course of the disease are unlikely to benefit from current treatment approaches, including lenalidomide

read more

First German hospital to implement MMprofiler (SKY92) in real-world setting

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 4, 2020: SkylineDx is excited to announce the scientific collaboration with the Multiple Myeloma (blood cancer) specialized department of the Wuerzburg University Medical Center II

read more

SkylineDx confirms positive results first independent validation skin cancer test

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 30, 2019: SkylineDx announced, during the European Society for Medical Oncology congress (Barcelona, EU), that it successfully validated the performance of their skin cancer

read more

SkylineDx and Mayo Clinic collaborate on implementing skin cancer test in clinical practice

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 24, 2019: SkylineDx announced at the 32nd Biennial Dermatology Symposium: The O’Leary Meeting 2019 in Rochester (MN, US) the launch of a pilot study it will conduct with the

read more

Combination of multiple myeloma diagnostics finds lenalidomide benefit

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 12, 2019: fast-progressing multiple myeloma (blood cancer) patients of 65 years and older that won’t undergo a stem cell transplantation live 42 months longer when treated with

read more

03 September 2019 FD release

Translation of Dutch newspaper (Het Financieele Dagblad) article written by Thieu Vaessen. Source can be found via this link.    ***   Van Herk puts € 20 million into diagnostics company for skin cancer   The

read more

Dutch company receives EUR 20 million for skin cancer diagnostic test

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 2, 2019: Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing

read more

UK Commercialization Partner for Multiple Myeloma Diagnostics

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), July 25th, 2019: hematologists and multiple myeloma (blood cancer) patients in the UK will have access to Dutch developed diagnostic test MMprofilerTM with SKY92 algorithm through the

read more

Dutch Hospital First to Use Multiple Myeloma Diagnostic Test

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), July 23rd, 2019: the academic hematology department of Erasmus Medical Center (EMC) is globally the first hospital to offer every multiple myeloma (blood cancer) patient an innovative

read more

Erasmus MC biedt als eerste test aan bij multipel myeloom

  ROTTERDAM en SAN DIEGO (Verenigde Staten), 23 juli 2019: de hematologie afdeling van het Erasmus Medisch Centrum (EMC) is wereldwijd het eerste ziekenhuis dat elke multipel myeloom (bloedkanker) patiënt een innovatieve diagnostische

read more

Dutch scale-up SkylineDx secures respected CAP/CLIA certification for US laboratory

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 26th, 2019: the Rotterdam headquartered diagnostics company has been granted CAP (College of American Pathologists) accreditation, following its CLIA (Clinical Laboratory Improvement

read more

Study Results Show Significant Improvement Multiple Myeloma Care

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 13th, 2019: a substantial number of blood cancer (multiple myeloma) patients could make more informed decisions on their treatment if more information becomes available for them and their

read more

Studieresultaten Tonen Significante Verbetering Multipel Myeloom Zorg

  ROTTERDAM en SAN DIEGO (Verenigde Staten), 13 juni 2019: een aanzienlijk aantal bloedkanker (multipel myeloom) patiënten kunnen beter beslissen over een behandeling als er meer informatie over hun diagnose beschikbaar komt voor hen en

read more

Dutch Multiple Myeloma Diagnostic Able To Guide Treatment

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), November 28, 2018: an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk

read more

Dutch government grants €2.7M for development skin cancer test

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 27, 2018: Netherlands Enterprise Agency (“Rijksdienst voor Ondernemend Nederland”), a part of the Ministry of Economic Affairs and Climate Policy, grants through a

read more

Nederlandse overheid financiert € 2,7M voor ontwikkeling huidkankertest

  ROTTERDAM en SAN DIEGO (USA), 27 september, 2018: Rijksdienst voor Ondernemend Nederland (RVO), een onderdeel van het ministerie van Economische Zaken en Klimaat, kent, middels Innovatiekrediet, € 2,7 miljoen toe aan de ontwikkeling van

read more

Groundbreaking algorithm predicts best treatment for cancer patient

  ROTTERDAM, the Netherlands and SAN DIEGO USA, July 30th, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels on the algorithm GESTURE [1] that links individual cancer patients to

read more

Baanbrekend algoritme voorspelt beste behandeling kankerpatiënt

  ROTTERDAM en SAN DIEGO (USA), 30 juli, 2018: Wetenschappelijk tijdschrift Nature Communications publiceerde 27 juli 2018 het onderzoekspaper van Joske Ubels over het GESTURE [1] algoritme dat individuele kankerpatiënten koppelt aan een

read more

Machine learning algorithm predicts treatment response in MM

  ROTTERDAM, the Netherlands and SAN DIEGO, USA, August 1, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels about a novel machine learning concept that derives predictive

read more

SkylineDx Poster Presentations at EHA Meeting Further Validate Use of MMprofilerTM with SKY92 in Multiple Myeloma

  SKY92 risk stratification at relapse provides additional prognostic information for standardrisk Multiple Myeloma patients   RNA-Seq based risk stratification in Multiple Myeloma patients validates SKY92 as a high-risk marker in the

read more

SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma

  Rotterdam, the Netherlands, January 31, 2018 – SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the

read more

SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler with SKY92 in Multiple Myeloma

  First Validation of SKY92 Prognostic Signature in Bortezomib-Thalidomide-Dexamethasone (VTD) Setting   Additional Data Yield Key Insights into Biology of Multiple Myeloma and Inform Design of Myeloma UK (MUK) Nine OPTIMUM Trial

read more

SKY92 Gene Signature Facilitates Cost-effective, Risk-stratified Treatment of Multiple Myeloma

  Poster Presentation at ISPOR European Congress Demonstrates Cost-savings and HealthGenerating Benefits of SKY92   Rotterdam, the Netherlands and Laguna Hills, CA, November 13, 2017 – SkylineDx announced new data from the 20th

read more

SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial

  ICR to Use SkylineDx’s MMprofiler™ Gene-Based Prognostic Signature in Phase IIb MUK nine High-risk Trial in Multiple Myeloma   Rotterdam, the Netherlands and Laguna Hills, CA, October 12, 2017 – SkylineDx today

read more

SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma (MM)

  Clinical Lymphoma, Myeloma and Leukemia Paper Validates Use of SKY92 and its Combination with International Staging System (ISS)   Rotterdam, the Netherlands and Laguna Hills, CA, July 25, 2017 – SkylineDx today announced the

read more

SkylineDx Presented New Algorithm Demonstrating Ability to Successfully Identify Gene Sets that are Informative of Cancer Treatment Specific Survival

  Presentation at BioSB 2017 Demonstrated Value of GESTURE™ for Identifying Patient Subgroups Likely to Benefit from Anti-Cancer Treatment   Rotterdam, the Netherlands and Laguna Hills, CA, April 10, 2017 – SkylineDx

read more

SkylineDx Announces Multiple Studies Being Presented at the 58th Annual ASH Meeting Reinforcing Utility of MMprofiler™ Gene-Based Prognostic Signature to Impact Treatment of Patients with Multiple Myeloma

  New Studies Demonstrate Value of Gene Expression Risk Profiling to Identify Ultra-High-Risk Multiple Myeloma Patients   Rotterdam, the Netherlands and Laguna Hills, CA, November 29, 2016 – SkylineDx today announced the

read more

SkylineDx Receives Notice of Allowance to Grant Patent for Prognostic SKY92 Gene Signature in Japan

  The Japanese Patent Office Has Notified SkylineDx of the Decision to Grant a Patent for the SKY92 Gene Signature   Rotterdam, the Netherlands, Laguna Hills, CA, Tokyo, Japan, October 11, 2016 - SkylineDx is pleased to announce

read more

SkylineDx and Consortium of Leading European Partners awarded multi-million Euro Horizon2020 grant from European Commission

  Project Focuses on Development of Gene Expression Profiling Tool to Predict Treatment Outcomes for Patients with Multiple Myeloma   Rotterdam, the Netherlands and Laguna Hills, CA, October 4, 2016 - SkylineDx today announced

read more

SkylineDx to Present New Data Demonstrating MMprofiler™ as Robust Prognostic Tool in Multiple Myeloma at the European Hematology Association 21st Annual Congress (EHA)

  Studies Support Validity of SKY92 as a Superior Predictor of Risk Stratification in Newly Diagnosed and Relapsed Patients   Rotterdam, the Netherlands and Laguna Hills, CA, May 31, 2016 - SkylineDx today announced the

read more

SkylineDx Supports Myeloma Awareness Month to Raise Awareness of a Serious and Difficult to Treat Disease

  ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., March 8, 2016 -- SkylineDx today announces its support for Myeloma Awareness Month, an effort conducted throughout the month of March by the International Myeloma Foundation (IMF) to

read more

SkylineDx to Present New Data Demonstrating Prognostic Value of MMprofiler™ in Multiple Myeloma at American Society of Hematology Annual Meeting

  Studies Support Use of MMprofiler™ for Stratifying High and Low-Risk in Newly Diagnosed Elderly and Relapsed Patients   MassGen Poster Highlights Use of MMprofiler™ in Phase II Modified RVD

read more

SkylineDx Receives CE-IVD Mark for MMprofiler™ -- Its Innovative Gene Signature-Based Test for Multiple Myeloma

  CE-IVD Approval Marks SkylineDx’s European Commercialization of its MMprofiler technology   Rotterdam, the Netherlands and Laguna Hills, CA, November 25, 2015 – SkylineDx, today announced they have received CE-IVD

read more

SKY92-ISS Superior to current markers in risk classification for myeloma survival

  Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients   Rotterdam, the Netherlands, 8 September 2015 – Researchers at

read more

SkylineDx appoints Leonard Kruimer as CFO Peter Schineller as CCO

  Key additions to the management team as SkylineDx accelerates its development of gene signature-based diagnostics and prepares for the launch of its first product   Rotterdam, The Netherlands, 19 August 2015 - SkylineDx, a

read more

More Accurate Prediction on Prognosis in Multiple Myeloma (bone marrow cancer)

  Test of Dutch-based SkylineDx gives patients better insight in their chances and enables clinicians to adjust their treatment   Rotterdam, 2 July 2015 – SkylineDx, an innovative biotechnology company specialising in the

read more

SkylineDx Presents an Abstract on Risk Identification for Multiple Myeloma Patients at the 20th Congress of the EHA

  Boston (U.S.) – Rotterdam (NL), June 8, 2015. On the 13th of June SkylineDx will present an abstract detailing the comparison of SKY92 GEP, IFISH AND ISS for risk identification in Multiple Myeloma (MM) patients and the clinical

read more